One may argue that linezolid was the pioneer among the oxazolidinone antibiotics. This chemical is an antibiotic that has been synthesised. It binds to rRNA and stops bacteria from making proteins. Additionally, it slows down the pace of translation elongation reactions and prevents the formation of the initiation complex during protein synthesis, both of which shorten the produced peptide chains. A number of infections have been approved for treatment with linezolid, including those caused by vancomycin-resistant Enterococcus faecium, Staphylococcus aureus pneumoniae in hospitals, complicated SSSIs, uncomplicated SSSIs caused by methicillin-susceptible S. aureus or Streptococcus pyogenes, and Streptococcus pneumoniae in community settings.